Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis

Journal of Drugs in Dermatology

Volumn 13, Issue 5, 2014, Pages 554-562

  Navarini, Alexander A ^a   Poulin, Yves ^b   Menter, Alan ^c   Gu, Yihua ^d   Teixeira, Henrique D ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Centre Dermatologique du Québec Metropolitan   (Canada)

^c BAYLOR RESEARCH INSTITUTE   (United States)

^d ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BODY REGIONS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ERYTHEMA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; SKIN EXFOLIATION; SKIN INDURATION; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMPARATIVE STUDY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; METHOTREXATE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900565389     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Robinson A. Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASII: why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. Mar. 2012;66(3):369-375.
2. Puzenat E, Bronsard V. Prey S. et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. Journal ol the European Academy of Dermatology and Venereology 2010;24:10-16.
3. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.
4. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10(2):7.
5. Mease PJ. Measures of psoriatic arthritis. Arthritis Care & Res. 2011;63 (S11):S64-S85.
6. Menter A. Gottlieb A, Feldman SR. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologies. J Am Acad Dermatol. May 2008;58(5):826-850.
7. Langley RG. Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. Oct. 2004;51(4):563-569.
8. Callen JP, Krueger GG, Lebwohl M. et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. Nov. 2003, 49(5):897-899.
9. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol. Jun. 2003;2(3):260-266.
10. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat. Jan 2004;1501:27-29.
11. Ashcroft DM. Wan Po AL, Williams HC. Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. Aug. 1999. 141(2):185-191.
12. Faria JR, Aarao AR. Jimenez LM, Silva OH, Avelleira JC. Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index). An Bras Dermatol. Sep-Oct. 2010;85(5):625-629.
13. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. Apr. 2000:142(4):728-732.
14. Feldman SR, Fleischer AB, Jr., Reboussin DM. et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. Jan 1996;106(1):183-186.
15. Sampogna F, Sera F, Mazzotti E, Pasqumi P. Picardi A, Abeni D. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol. Mar. 2003;139131:353-358; discussion 357
16. Berth-Jones J, Thompson J. Papp K. A study examining inter-rater and mtrarater reliability of a novel instalment for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol. Aug. 2008;159(2):407-412.
17. Harari M, Shani J, Hristakieva E, Stanimirovic A, Seidl W, Burdo A. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea. Int J Dermatol. Dec. 2000;39(12):913-918.
18. Ihtatho D, Fadzil MH, Affandi AM, Hussein SH. Area assessment of psoriasis lesion for PASI scoring. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:3446-3449.
19. Fadzil MHA, Ihtatho D, Affandi AM, Hussein SH. Objective assessment of psoriasis erythema for PASI scoring. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:4070-4073.
20. Wittkowski KM. Leonardi C, Gottlieb A, et al. Clinical symptoms of skin. nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One. 2011;6(6):e20279.
21. Rapaport MJ. PASI 75. J Am Acad Dermatol. 2005;52:183-184.
22. Saurat JH, Stingl G, Dubertret L. et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.
23. Kragballe K, Menter A, Lebwohl M. Tebbey PW. Van De Kerkhof PC. Long-Term Management of Scalp Psoriasis: Perspectives from the International Psoriasis Council. J Dermatolog Treat. Mar. 28 2012.
24. Van De Kerkhof PC. Murphy GM. Austad J, Ljungberg A, Cambazard F Duvold LB. Psoriasis of the face and flexures. JDermatologTreat. 2007;18(6):351-360.
25. Ludwig MW, Oliveira Mda S. Muller MC, Moraes JF. Quality of life and site of the lesion in dermatological patients. An Bras Dermatol. Mar-Apr. 2009;84(2):143-150.
26. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. Mar. 2 1995;332(9):581-588.
27. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341-350.
28. Kimball AB, Sundaram M, Mulani PM, Bao Y. Quality of life effects of psoriasis skin symptoms affecting different body regions. J Am Acad Dermatol. 2012;66(4, Suppl1): AB202.